Drug Trial Radar · NCT03781414
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
129
Actual
Start
Oct 7, 2019
Primary completion
Apr 20, 2023
Study completion Apr 20, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
Conditions
- Liver Transplant Rejection
Interventions
CFZ533Biological
Comparison with standard of care immunosuppression
Tacrolimus - MMF - corticosteroidsDrug
Standard of care immunosuppresive regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Composite Event (Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death) Over 12 MonthsTime frame: Baseline to Month 12
Locations
29 sites in 10 countries. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
University of Colorado Hospital - Aurora
Aurora, Colorado
Northwestern University
Chicago, Illinois
Henry Ford Hospital
Detroit, Michigan
Wash U School of Medicine
St Louis, Missouri
Duke Univ Medical Center
Durham, North Carolina
University Of Cincinnati
Cincinnati, Ohio
Medical University of South Carolina MUSC
Charleston, South Carolina
The Methodist Hospital
Houston, Texas
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Chambray-lès-Tours, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Pisa, PI, Italy
Novartis Investigative Site
Rotterdam, South Holland, Netherlands
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.